MCUR

Mind Cure Health Inc.

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, Sept. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of d... Read More...

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally. VANCOUVER, BC, Aug. 4, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), ... Read More...

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. VANCOUVER, BC, July 13, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technolo... Read More...

MINDCURE Adopts Advance Notice Policy

VANCOUVER, BC, July 12, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company wit... Read More...

Maxim Group Initiates Coverage of Mind Cure Health

VANCOUVER, BC, June 30, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health I... Read More...